Navigation Links
Simpler Anemia Treatment May Help Kidney Patients
Date:10/19/2007

Newer drug is given just once per month, experts say

FRIDAY, Oct. 19 (HealthDay News) -- A new approach for treating anemia in patients with severe kidney disease could help improve patients' quality of life, according to a U.S. study.

Compared with conventional therapy, giving patients an anti-anemia drug as infrequently as once a month could simplify anemia management, concluded Dr. Nathan Levin, of the Renal Research Institute in New York, and colleagues.

The findings are published in the Oct. 20 issue of The Lancet.

Conventional therapy with epoetin (a synthetic form of human erythropoietin that promotes red blood cell production) requires frequent administrations (at least once weekly), changes of dose, and close monitoring of hemoglobin concentrations.

In this study involving patients on dialysis, the researchers compared the use of a long-acting erythropoieses-stimulating agent variant of epoetin (methoxy polyethylene glycol-epoetin beta) given intravenously at 2-week or 4-week intervals, with epoetin treatment one to three times per week.

All 673 patients in the study received conventional epoetin treatment for the first four weeks of the study. After that, one group of patients received methoxy polyethylene glycol-epoetin beta every two weeks, another group received methoxy polyethylene glycol-epoetin beta every four weeks, and the third group continued receiving conventional epoetin treatment.

After about 42 weeks, there were no statistically significant differences in hemoglobin concentrations between the three groups. Based on their findings, the researchers recommended that methoxy polyethylene glycol-epoetin beta be introduced as an option for simplified management of anemia in patients on dialysis.

However, the authors of an accompanying Comment article called for more research.

"Before we can concur on a precise clinical role for this molecule, we need to explore issues other than simply the non-inferiority with other epoetins to reach certain unvalidated surrogates. Different doses and molecular characteristics of epoetins may affect patient-level endpoints, independent of achieved hemoglobin. When these issues are examined, we might be truly confident that a newer molecule is non-inferior to existing ones," wrote Dr. Rowan Walker of the Royal Melbourne Hospital and Monash University Alfred Hospital in Melbourne, Australia, and Dr. Giovanni Strippoli, of the University of Sydney, Australia, and the Mario Negri Sud Consortium in Chieti, Italy.

More information

The U.S. National Institute on Diabetes and Digestive and Kidney Diseases has more about anemia.



-- Robert Preidt



SOURCE: The Lancet, news release, Oct. 19, 2007


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Surgeons Develop Simpler Way to Cure Atrial Fibrillation
2. Detection of Malignant Breast Tumors Made Simpler and More Effective
3. Liver Regeneration may Be Simpler Than Previously Thought
4. Fight anemia by fortifying crops with iron!!!!!!!!
5. Doctors advice early anemia tests
6. Anemia Treatment for Cancer Patients
7. Anemia Treatment for Cancer Patients
8. Anemia Treatment for Cancer Patients Might Not be a Good Idea.
9. Anemia may Lead to Physical Decline
10. Gene to identify risk of stroke in sickle cell anemia
11. New treatment for babies with sickle cell anemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 If ... Leaders Scholarship is any indication, the future is in ... at www.diabetesscholars.org by the Diabetes Scholars Foundation ... the way of academic and community service excellence. ... since 2012, and continues to advocate for people with ...
Breaking Medicine Technology: